New hope for kids with severe colitis: etrasimod trial opens

NCT ID NCT07470879

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Mar 25, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This study tests an oral medication called etrasimod in children aged 2 to 12 with moderate to severe ulcerative colitis. The goal is to see if it can safely reduce inflammation and bring about remission over 52 weeks. Participants who finish may continue treatment for up to 5 years total.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Québec - Université Laval
RECRUITING

Québec, Quebec, G1V4G2, Canada
Centrum Zdrowia MDM
NOT_YET_RECRUITING

Warsaw, Masovian Voivodeship, 00-189, Poland
Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero
NOT_YET_RECRUITING

Katowice, 40-600, Poland
Japanese Red Cross Kumamoto Hospital
RECRUITING

Kumamoto, 861-8520, Japan
Juntendo University Hospital
RECRUITING

Tokyo, 113-8431, Japan
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś
RECRUITING

Warsaw, Masovian Voivodeship, 04-501, Poland
Saitama Prefectural Children's Medical Center
RECRUITING

Saitama-shi, Saitama, 330-8777, Japan
Universitaetsklinikum Tuebingen
NOT_YET_RECRUITING

Tübingen, 72076, Germany
Universitätsklinikum Leipzig
NOT_YET_RECRUITING

Leipzig, Saxony, 04103, Germany

Conditions

Explore the condition pages connected to this study.

COLITIS, ULCERATIVE